Actively Recruiting
A Registry to Investigate Real-world Natural History, Impact of Therapies and Patterns of Progression of AL Amyloidosis (ReAL)
Led by Fondazione IRCCS Policlinico San Matteo di Pavia · Updated on 2026-04-16
5000
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to create a large registry of patients diagnosed with AL amyloidosis to better understand the natural course of this condition in everyday medical settings. By collecting data at diagnosis and throughout follow-up, the study seeks to describe how the disease progresses and to develop reliable models for predicting outcomes, treatment responses, and relapses at any stage of the illness. Participants in this observational study contribute information collected during their routine clinical care without receiving experimental treatments. The registry includes data from patients who have not yet received treatment for AL amyloidosis, with retrospective data also collected where available. Participants are followed over time at the participating centers as part of their usual care. During the study, researchers gather clinical information at diagnosis and during follow-up visits. Outcome measures focus on building and maintaining the registry over a five-year period. The study does not assign specific treatments but observes patients in real-world settings to understand the impact of therapies and progression patterns. Participation may last several years as data accumulates to support future research and improve patient care.
CONDITIONS
Brief Title
A Registry of AL Amyloidosis (ReAL)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of systemic AL amyloidosis
- No previous treatment for AL amyloidosis (treatment-nave)
- Age 18 years or older
- Ability to understand and willingness to sign informed consent
- Planned or ongoing follow-up at a participating medical center
You will not qualify if you...
- Diagnosis other than AL amyloidosis
- Previous treatment for AL amyloidosis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - At diagnosis
Participants undergo assessments at diagnosis to collect data about AL amyloidosis.
Duration - Up to 5 years
Participants are observed over several years to collect data about disease progression and treatment impact in a real-world setting.
Trial Site Locations
Total: 1 location
1
Fondazione IRCCS Policlinico San Matteo
Pavia, Italy, 27100
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here